S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:JYNT

The Joint Stock Forecast, Price & News

$82.41
-0.33 (-0.40 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$80.80
$84.09
50-Day Range
$78.50
$107.30
52-Week Range
$18.10
$111.06
Volume121,503 shs
Average Volume220,687 shs
Market Capitalization$1.18 billion
P/E Ratio70.44
Dividend YieldN/A
Beta1.31
30 days | 90 days | 365 days | Advanced Chart
Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for The Joint and its competitors with MarketBeat's FREE daily newsletter.


The Joint logo

About The Joint

The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics. The Franchise Operations segment includes the operating activities of the franchise business unit. The Joint was founded by Fred Gerretzen, Charles Barnwell, John Leonesio, Todd Welker, Barbara Holland, Steven P. Colmar, Craig P. Colmar and Richard Rees on March 10, 2010 and is headquartered in Scottsdale, AZ.

Headlines

JYNT INVESTOR NOTICE: ROSEN, LEADING INVESTOR...
October 18, 2021 |  benzinga.com
The Joint Corp. (NASDAQ:JYNT) Short Interest Up 28.3% in September
October 18, 2021 |  americanbankingnews.com
The Joint (NASDAQ:JYNT) Shares Gap Up to $78.50
October 14, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Patent owners & lessors
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JYNT
Employees
325
Year Founded
N/A

Sales & Book Value

Annual Sales
$58.68 million
Cash Flow
$0.39 per share
Book Value
$1.48 per share

Profitability

Net Income
$13.17 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.18 billion
Next Earnings Date
11/4/2021 (Confirmed)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.66 out of 5 stars

Medical Sector

51st out of 1,359 stocks

Patent Owners & Lessors Industry

2nd out of 12 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












The Joint (NASDAQ:JYNT) Frequently Asked Questions

Is The Joint a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for The Joint in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" The Joint stock.
View analyst ratings for The Joint
or view top-rated stocks.

What stocks does MarketBeat like better than The Joint?

Wall Street analysts have given The Joint a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Joint wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting The Joint?

The Joint saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,080,000 shares, an increase of 28.3% from the September 15th total of 842,000 shares. Based on an average daily volume of 219,300 shares, the days-to-cover ratio is currently 4.9 days. Currently, 7.7% of the company's shares are sold short.
View The Joint's Short Interest
.

When is The Joint's next earnings date?

The Joint is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for The Joint
.

How can I listen to The Joint's earnings call?

The Joint will be holding an earnings conference call on Thursday, November 4th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "3834499".

How were The Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings results on Thursday, August, 5th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.13. The firm earned $20.22 million during the quarter, compared to analyst estimates of $17.58 million. The Joint had a trailing twelve-month return on equity of 41.46% and a net margin of 24.55%.
View The Joint's earnings history
.

How has The Joint's stock price been impacted by COVID-19 (Coronavirus)?

The Joint's stock was trading at $13.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JYNT shares have increased by 505.5% and is now trading at $82.41.
View which stocks have been most impacted by COVID-19
.

What guidance has The Joint issued on next quarter's earnings?

The Joint updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $77 million-$79 million, compared to the consensus revenue estimate of $75.85 million.

What price target have analysts set for JYNT?

6 brokerages have issued 1 year price targets for The Joint's stock. Their forecasts range from $54.00 to $150.00. On average, they anticipate The Joint's stock price to reach $107.00 in the next year. This suggests a possible upside of 29.8% from the stock's current price.
View analysts' price targets for The Joint
or view top-rated stocks among Wall Street analysts.

Who are The Joint's key executives?

The Joint's management team includes the following people:
  • Peter D. Holt, President, Chief Executive Officer & Director
  • Jorge Armenteros, Vice President-Operations
  • Jacob Singleton, Chief Financial Officer & Controller (LinkedIn Profile)
  • Manjula Sriram, Vice President-Information Technology
  • Steve Knauf, Executive Director-Chiropractic & Compliance

What is Peter D. Holt's approval rating as The Joint's CEO?

87 employees have rated The Joint CEO Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among The Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of The Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), salesforce.com (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did The Joint IPO?

(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is The Joint's stock symbol?

The Joint trades on the NASDAQ under the ticker symbol "JYNT."

Who are The Joint's major shareholders?

The Joint's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%), Crossmark Global Holdings Inc. (0.06%), Louisiana State Employees Retirement System (0.05%), Wesbanco Bank Inc. (0.05%), Robeco Institutional Asset Management B.V. (0.04%) and Mesirow Financial Investment Management Inc. (0.04%). Company insiders that own The Joint stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel and Ronald V Davella.
View institutional ownership trends for The Joint
.

Which institutional investors are selling The Joint stock?

JYNT stock was sold by a variety of institutional investors in the last quarter, including Resource Planning Group, Crossmark Global Holdings Inc., and Mesirow Financial Investment Management Inc.. Company insiders that have sold The Joint company stock in the last year include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, and Ronald V Davella.
View insider buying and selling activity for The Joint
or view top insider-selling stocks.

Which institutional investors are buying The Joint stock?

JYNT stock was acquired by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Nkcfo LLC, Ellsworth Advisors LLC, State of Alaska Department of Revenue, Oregon Public Employees Retirement Fund, Louisiana State Employees Retirement System, and Wesbanco Bank Inc.. Company insiders that have bought The Joint stock in the last two years include Bandera Partners Llc, and Jake Singleton.
View insider buying and selling activity for The Joint
or or view top insider-buying stocks.

How do I buy shares of The Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $82.41.

How much money does The Joint make?

The Joint has a market capitalization of $1.18 billion and generates $58.68 million in revenue each year. The company earns $13.17 million in net income (profit) each year or $0.30 on an earnings per share basis.

How many employees does The Joint have?

The Joint employs 325 workers across the globe.

What is The Joint's official website?

The official website for The Joint is www.thejoint.com.

Where are The Joint's headquarters?

How can I contact The Joint?

The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at (480) 245-5960 or via email at [email protected].


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.